Aims Despite intensive lipid-lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This ...

Heart failure is the final outcome of most cardiovascular diseases and shares risk factors with other cardiovascular pathologies. Among these, inflammation plays a central role in disease progression ...

Aims Diabetes mellitus remains a prevalent condition worldwide and a significant risk factor for atherosclerotic cardiovascular disease. Recent evidence suggests the use of glucose-lowering therapie.....

Browse through a range of inspiring news stories from the University of Lincoln, featuring leading research, campus events, and student and alumni success stories.

Sotagliflozin reduced MACE, with independent reductions in myocardial infarction and stroke, among patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. The ischae...

Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind ...

Based on FLOW trial results, the FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.

This study found that individual SGLT-2 inhibitors demonstrated comparable cardiovascular effectiveness at clinically effective doses, though low-dose dapagliflozin showed a reduced benefit for heart ...

Su, Zhao, Jiang and colleagues identify IGFBP6 as an intrinsic downregulator of the inflammatory response lost in disturbed flow-induced atherosclerotic plaque development, suggesting that its restora...

Click on the title to browse this issue

The kidney tubules have a crucial role in homeostasis as they modify and regulate the kidney filtrate. This Review examines current data on how filtered proteins are processed along the kidney tubule,...

Increased activity of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome–IL-1β pathway is observed in obesity and contributes to the development of type 2 diabetes and its compli...

In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist, a soluble g...

As part of the SWEETSTONE trial, the authors report the ability of the sodium-glucose cotransporter 2 inhibitor empagliflozin to reduce the likelihood of kidney stone formation in individuals without ...

We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.

Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...

The system checks patients' ECG heart traces for subtle early warning signs.

Jamie Lonsdale made a donor plea on Facebook and was delighted when Lauren Lane answered the call.

Nature Medicine asks experts to explain the research priorities for the field of GLP-1 receptor agonists such as semaglutide, from sex differences to how they might treat addiction.

Read the winning essay from the Young Science Writer of the Year 2024 award

Our Small Grant Awards offer funding of up to £30,000 for a maximum of 12 months, for UK-based early career researchers.